LivaNova introduces 2030 financial targets at Investor Day

LivaNova (LIVN) hosted its 2025 Investor Day and presented its comprehensive strategic roadmap and long-range financial plan. LivaNova’s 2030 financial targets include: High-single-digit-plus revenue compound annual growth rate; Adjusted annual operating margin above 20% over the next three years, targeting high twenties by 2030; Earnings-per-share CAGR in the low double digits to mid-teens; Adjusted free cash flow conversion above 80%. “We are confident in our ability to deliver on the targets we outlined today. LivaNova’s talented team is focused on a revitalized innovation strategy and operational excellence,” said Vladimir Makatsaria, Chief Executive Officer of LivaNova. “The leadership positions we hold in our Epilepsy and Cardiopulmonary businesses give us a strong foundation that provides predictable growth, margin expansion, and consistent cash generation, allowing us to invest in our future.”